Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mature T-cell and NK-cell non-Hodgkin lymphoma, also called peripheral T-cell lymphoma (PTCL), is described in the packet definition as a lymphoma not frequently seen in the western hemisphere. According to that definition, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative entities named in the definition include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma. The packet does not certify prevalence, age of onset, or associated genes.
Symptom and phenotype data are not certified in this packet, so no clinical features are described here.
No causative genes or inheritance pattern are listed in this packet, and the cause is not described in the supplied fields. The packet lists related subtypes, including T-cell prolymphocytic leukemia, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, aggressive NK-cell leukemia, and T-cell large granular lymphocyte leukemia, among others.
Diagnostic methods are not certified in this packet.
The packet's FDA records list two approved treatments with ACTIVE market status. Belinostat (BELEODAQ) was approved through a New Drug Application reviewed by CDER on 2014-07-03, and brentuximab vedotin (ADCETRIS) was approved through a Biologics License Application on 2011-08-19. The packet's orphan drug records describe belinostat as indicated for peripheral T-cell lymphoma and brentuximab vedotin for peripheral T-cell lymphoma, including several named subtypes. Other orphan drug records in the packet, such as the one for valemetostat tosylate, carry DESIGNATED status, which is not approval; alisertib, devimistat, and fenretinide records are marked WITHDRAWN. Foundational therapies and management guidance are not certified in this packet.
90 trials found
Natural history data are not certified in this packet. The definition characterizes most mature T- and NK-cell lymphomas as among the most aggressive hematopoietic neoplasms, with anaplastic large cell lymphoma noted as an exception.
The packet lists active ClinicalTrials.gov records, including NCT03113500, a Phase 2 study of brentuximab vedotin with combination chemotherapy in CD30-positive peripheral T-cell lymphoma (City of Hope Medical Center; active, not recruiting; 2017-12-04 to 2027-04-25); NCT04703192, a Phase 2 study of valemetostat tosylate in relapsed or refractory peripheral T-cell lymphoma (Daiichi Sankyo; active, not recruiting; 2021-06-03 to 2029-06-19); and NCT03922724, a Phase 2 study of allogeneic hematopoietic cell transplantation (National Cancer Institute; active, not recruiting; 2019-04-18 to 2030-10-31). No patient organizations are listed in the packet.
Data assembled from 4 of 12 sources · Last updated Nov 18, 2026, 6:00 AM UTC
Genetic and Rare Diseases Info Center